{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings",
  "queries": [
    "https://consensus.app/search/partial-epigenetic-osk-reprogramming/MrfdVHnxRN-eVzL4d0wKhA/"
  ],
  "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.",
  "primary_comparison_count": 10,
  "primary_comparisons": [
    {
      "pmid": "38381405",
      "doi": "10.1089/cell.2023.0072",
      "source_type": "primary study report",
      "study_group": "PMID38381405",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Remaining versus total lifespan and actual control",
      "result_comparison": "Observed Consensus correctly preserves the remaining-life denominator. Original Methods/Results show about 8.9 versus 18.5 remaining weeks after treatment at 124 weeks, with concurrent buffer controls and a historical control-AAV argument. This supports a real animal signal with delivery-control limits, not doubled total life or human efficacy.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/38381405/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-0-9-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\38381405-s1-p1-2-3-4-7-8.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\38381405-s2-p1-3-4-5-6-7-10-11.json"
      ]
    },
    {
      "pmid": "38381405",
      "doi": "10.1089/cell.2023.0072",
      "source_type": "primary study report",
      "study_group": "PMID38381405",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Survivor-selected methylation and immortalized human cells",
      "result_comparison": "Provider summarizes older-donor keratinocyte clock reversal. Actual M/R identify an immortalized scalp-derived line, puromycin survivor selection and terminal healthy-animal selection for mouse methylation. These facts constrain selection and recipient interpretation; the human component is not an adult clinical intervention.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/38381405/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-0-9-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\38381405-s1-p1-2-3-4-7-8.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\38381405-s2-p1-3-4-5-6-7-10-11.json"
      ]
    },
    {
      "pmid": "35390271",
      "doi": "10.7554/eLife.71624",
      "source_type": "primary study report",
      "study_group": "PMID35390271",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Identity recovery versus uninterrupted identity",
      "result_comparison": "Provider describes human-cell rejuvenation without erased identity, while its fuller wording notes no permanent loss. Actual M/R explicitly show temporary fibroblast identity suppression, sorting of intermediate states and later recovery. Retained final identity does not prove no intermediate dedifferentiation or universal safe control.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/35390271/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-0-9-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\35390271-s1-p0-4-7-17-22-23.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\35390271-s3-p1-2-14-16.json"
      ]
    },
    {
      "pmid": "35390271",
      "doi": "10.7554/eLife.71624",
      "source_type": "primary study report",
      "study_group": "PMID35390271",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Clock years versus independently measured function",
      "result_comparison": "Provider reports approximately thirty clock-years and collagen recovery. Actual Results retain those findings but show variable migration that did not correlate with clocks, multiple unresponsive clocks and no telomere-clock rejuvenation. This directly bounds clock-to-function surrogacy without discarding real partial cellular function.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/35390271/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-0-9-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\35390271-s1-p0-4-7-17-22-23.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\35390271-s3-p1-2-14-16.json"
      ]
    },
    {
      "pmid": "32210226",
      "doi": "10.1038/s41467-020-15174-3",
      "source_type": "primary study report",
      "study_group": "PMID32210226",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Human donors versus human recipients",
      "result_comparison": "Provider correctly separates cell culture and grafts from systemic patients. Original Methods identify human donors and immunocompromised mouse recipients; actual force benefit is in mouse muscle, whereas human-cell graft benefit is assessed by mouse bioluminescence. No human strength or clinical-healthspan result is claimed.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/32210226/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-0-9-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\32210226-s1-p6-15-17-18-19.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\32210226-s2-p3-4-6-35-36.json"
      ]
    },
    {
      "pmid": "33268865",
      "doi": "10.1038/s41586-020-2975-4",
      "source_type": "primary study report",
      "study_group": "RETINAL-OSK-PLATFORM",
      "access_depth": "full_text_partial",
      "consensus_aspect": "TET dependence and demethylation insufficiency",
      "result_comparison": "Provider gives TET-related regenerative benefit largely through reviews. Selected original Results confirm Tet1/Tet2/TDG dependence, but also show global Tet1 catalytic demethylation alone did not protect or regenerate. Actual vision improvement is retained while rejecting sufficiency of a younger methylation state alone.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/33268865/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-18-27-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\33268865-s3-p0-1.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\33268865-s5-p0-1.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\33268865-s6-p0-1-2.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\33268865-s8-p0-16-21-28-34.json"
      ]
    },
    {
      "pmid": "33268865",
      "doi": "10.1038/s41586-020-2975-4",
      "source_type": "primary study report",
      "study_group": "RETINAL-OSK-PLATFORM",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Clock construction and local functional boundary",
      "result_comparison": "The provider emphasizes local retinal efficacy. Original Methods use blinded optomotor assessment and separate test samples, but clock-feature selection includes injury and OSK-response associations; original Results do not show the oldest visual-acuity benefit. Independent marker samples are useful but do not make the score a universal prospective clinical surrogate.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/33268865/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-18-27-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\33268865-s3-p0-1.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\33268865-s5-p0-1.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\33268865-s6-p0-1-2.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\33268865-s8-p0-16-21-28-34.json"
      ]
    },
    {
      "pmid": "36287172",
      "doi": "10.18632/aging.204347",
      "source_type": "primary study report",
      "study_group": "PMID36287172",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Unaddressed organism and expression-duration contrast",
      "result_comparison": "Provider largely discusses rodent positives and does not resolve this requested original organism. Actual M/R establish Drosophila, adult expression without embryonic induction, temperature-matched controls, cyclic survival benefits and continuous-expression detriment. It is neither a mouse senolytic trial nor a human treatment, and its mortality modeling complicates a universal aging-rate reduction claim.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/36287172/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-0-9-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\36287172-s1-p0-4-13-17-21-22.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\body-presentation-receipts\\36287172-s3-p2-19-22.json"
      ]
    },
    {
      "pmid": "29985406",
      "doi": "10.1038/s41467-018-05059-x",
      "source_type": "primary study report",
      "study_group": "PMID29985406",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "c-Myc removal and safety limits",
      "result_comparison": "Provider suggests omission of c-Myc reduces tumorigenesis, which may be valid in specific later systems. The examined original AAV abstract nevertheless reports full in vivo reprogramming without c-Myc, teratomas and vector integration. Omitting one oncogene is not a general safety certificate; full and controlled partial protocols remain distinct.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/29985406/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-60-69-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "39259812",
      "doi": "10.1126/scitranslmed.adg1777",
      "source_type": "primary study report",
      "study_group": "PMID39259812",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Observed tumor incidence versus universal safety",
      "result_comparison": "Provider retains aged-cell-targeted OSK survival and wound-healing positives. The original abstract reports no changed observed tumor incidence in its mouse setting. That is useful bounded feasibility evidence rather than proof of absent neoplasia across deliveries, humans or longer follow-up.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/39259812/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\examinations\\original-18-27-10000.json"
      ],
      "body_receipts": []
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\partial-reprogramming-human-aging\\consensus-browser-2026-10-13.json",
      "sha256": "c672b44d134a4d7f70dff3ce85920e6cad33272cb48ad68c75d688af7ea93d17"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-13",
  "completed_utc": "2026-10-13T17:35:23.521745+00:00",
  "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
}